2015 American Transplant Congress

May 2-6, 2015 in Philadelphia, Pennsylvania

View by Title View Sessions

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

B Cell Depletion With an Anti-CD20 Antibody Enhances Alloreactive Memory T Cell Response After Transplantation

J. Marino, P. Crosby Bertorini, J. Paster, A. Trowell, K. Briggs, L. Maxwell, G. Benichou.
B Cell MicroRNA as Biomarkers for Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder

A. Harris-Arnold, V. Kaul, S. Shaffert, O. Hatton, C. Esquivel, S. Krams, O. Martinez.
B-Cell Activation in Acute Kidney Injury and Delayed Graft Function

M. Schiffer,¹ F. Wiehler,¹ R. Song,¹ R. Chen,¹ L. Schiffer,¹ M. Mengel,² H. Haller,¹ F. Gueler.¹
B-Cell Tolerance to Donor Alloantigens

A. Patil, M. Climov, A. Matar, A. Musa, E. Harrington, D. Sachs, R. Duran-Struuck, C. Huang.
B7-H1 Deficiency in Liver Allografts Leads to CD8-Mediated Acute Vascular Rejection

M. Morita, D. Joyce, J. Fung, S. Qian, R. Fairchild, L. Lu.
BAFF Binding to T Cell-Expressed BAFF-R Promotes Follicular Helper T Cell Proliferation and GC B Cell Responses

M. Chen,¹ Q. Li,¹ W. Stohl,² S. Zheng,² X. He,¹ Z. Guo.¹
Banff Criteria Are Inadequate to Assess Chronic Renal Allograft Injury 10 Years Post-Transplantation

L. Cornell, W. Park, F. Cosio, M. Stegall.
Bariatric Surgery Prolongs Allograft Survival by Promoting Th2 Conditions

M. Quante, A. ElKhal, H. Rodriguez, R. Abdi, F. Krenzien, H. Uehara, S. Tullius.
Basiliximab Induction With Delayed Tacrolimus Initiation up to 14 Days Post Liver Transplantation Maintains Excellent Clinical Outcomes While Preserving Renal Function

J. Werth, W. Ally, D. Maluf, S. Pelletier.
Belatacept Based Immunosuppression and Incidence of Proteinuria in Kidney Transplant Recipients

R. Villicana, A. Peng, J. Kahwaji, J. Choi, A. Vo, S. Jordan.
Belatacept in a Community Hospital Adult Kidney Transplant Program

D. Nikolaenko, Q. Chaudhry, H. Smith, C. Shadur.
Belatacept Treatment Through Home Infusion as a Safe and Reasonable Alternative to Intitution-Based Treatment: A Retrospective Analysis of Medical Records

T. Kou,¹ A. Deshmukh,¹ J. Preston,¹ A. Gomez,¹ S. Rafanelli,² K. Calderon.¹
Belatacept-Treated Patients Had Better Graft Survival at 7-Years Post-Transplant Compared With Cyclosporine-Treated Patients: Final Results from BENEFIT

F. Vincenti,¹ J. Grinyó,² L. Rostaing,³ K. Rice,⁴ S. Steinberg,⁵ M. Moal,⁶ M. Polinsky,⁷ U. Meier-Kriesche,⁷ C. Larsen.⁸
Beneficial Effects of Controlling Peritransplant Inflammation in Total Pancreatectomy With Islet Autotransplantation: A Single Center Experience With Large Cohort of Patients

M. Takita,¹ M. Kanak,² R. Shahbazov,¹ G. Yoshimatsu,¹ M. Lawrence,¹ A. Dabous,³ P. Kim,³ N. Onaca,³ B. Naziruddin,³ M. Levy.³
Bidirectional Regulation and IL35 Surface Expression By Treg Cells

Y. Tomita, W. Burlingham.
Biliary Complication After Living Donor Liver Transplantation According to Biliary Reconstruction Methods

J. Lee,^1,2 J. Lee,^1,2 D. Han,^1,2 J. Lee,³ M. Ju,^1,2 M. Kim,^1,2 G. Choi,^1,2 J. Choi,^1,2 S. Kim,^1,2 D. Joo.^1,2
Bioengineering Liver Allografts through Organ Scaffold Recellularization

J. Woodall, J. Langford, C. Klassen, J. Harrison, D. Parsell, U. Dhru, R. Barth, J. LaMattina.
Biomarker for Calcineurin Inhibitors Nephrotoxicity in Solid Organ Transplantation: Validation of a Urine Gene Expression Panel

D. Maluf, R. Gehrau, J. Suh, K. Brayman, C. Bustamante, M. Edmunds, P. Darvishi, V. Mas.
Biomarker Panel Profile for Identification of High-Risk Patients After Heart Transplantation

M. Barten,¹ M.-T. Dieterlen,² J. Garbade,² F. Mohr.²
Biomarkers of Deceased Donors for the Prediction of Renal Allograft Outcomes

S. Kang,¹ H. Im,¹ J. Lee,¹ T. Koo,¹ S. Lee,² S. Park,³ S.-J. Kim,⁴ C. Ahn,¹ J. Yang.¹
Biopsychronology: Live Confocal Imaging of Biopsies to Assess Organ Function

M. Ashraf,¹ D. Fries,² W. Streif,³ F. Aigner,¹ P. Hengster,¹ J. Troppmair,¹ M. Hermann.²
Birth Weight as a Marker of Nephron Mass: Impact on Renal Allograft Function

T. Schachtner,^1,2 P. Reinke.^1,2
Birth Weight as a Marker of Nephron Mass: Predicting Living Kidney Donor Outcomes

T. Schachtner,^1,2 P. Reinke.^1,2
BK Virus-Specific Polyfunctional CD8+ T Cells Predicts Successful Control of BK Viremia After Kidney Transplantation

J. Schaenman,¹ Y. Korin,² T. Sidwell,² F. Kandarian,² N. Harre,² P.-T. Pham,³ S. Bunnapradist,³ G. Danovitch,³ J. Veale,⁴ H. Gritsch,⁴ E. Reed.²
Bladder Drainage of Pancreas Transplants Alone: Friend or Foe?

M. Bellini,¹ G. Spoletini,² S. Reddy,¹ J. Gilbert,¹ I. Quiroga,¹ R. Ploeg,¹ E. Sharples,³ S. Sinha,¹ A. Vaidya,¹ P. Friend.¹
Blocking CD4 T Cell Helper Functions Improves Efficacy of ATG Treatment in Sensitized Transplant Recipients

K. Ayasoufi, X. Wang, H. Yu, V. Gorbacheva, F. Ran, R. Fairchild, A. Valujskikh.
Blocking CD40/CD154 Co-Stimulation Prevents Acute Antibody-Mediated Renal Allograft Rejection Induced by Memory CD4 T Cells

V. Gorbacheva, R. Fan, A. Valujskikh.
Blood Gene Expression at 3 Months Post-Transplantation Predicts 1-Year Histological Features in Renal Transplantation

R. Danger,^1,2 K. Renaudin,^1,3,4 C. Paul,¹ G. Couvrat-Desvergnes,^1,3 J. Lozano,⁵ A. Sanchez-Fueyo,^2,5 V. Meas-Yedid,⁶ J. Olivo-Marin,⁶ E. Thervet,⁷ J. Dantal,^1,3,4 A. Moreau,^1,3,4 J.-P. Duong Van Huyen,⁸ J.-P. Soulillou,^1,3,4 M. Giral,^1,3,4 S. Brouard.^1,3,4
Blood Gene Expression Profiling in a Randomized Controlled Trial of rATG Vs. IL2RA Induction Reveals the Differences in Immune Impact and Mechanisms

K. Chavin,¹ D. Taber,¹ S. Kurian,² T. Gelbart,² N. Pilch,¹ S. Nadig,¹ J. McGillicuddy,¹ T. Srinivas,¹ C. Bratton,¹ P. Baliga,¹ D. Salomon.²
Blood Pressure Evaluation by Three Different Modalities in Living Kidney Donors

Z. Zaky, G. Thomas, S. Gebreselassie, E. Poggio.
Body Mass Index (BMI) Mismatch in Deceased Kidney Donation Is an Independent Risk Factor for Graft Failure

O. Staeck,¹ D. Khadzhynov,¹ M. Mahn,² K. Budde,¹ F. Fuller,² F. Halleck.¹
Boosting the Adaptive Immune Response Prevents the High Incidence of Herpes Zoster After Lung or Heart Transplantation

N. van Besouw,¹ S. Roest,² J. Zuijderwijk,¹ R. de Kuiper,¹ J. van Weezel,³ A. van der Eijk,⁴ W. Weimar,¹ P. Hal,³ O. Manintveld.²
Bortezomib Treatment in Antibody Mediated Rejection After Kidney Transplantation

J. Lee,¹ J. Lee,¹ B. Kim,² Y. Park,³ M. Ju,¹ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
Bortezomib-Based Multi-Modality Protocol for Donor-Specific Antibody Treatment in Lung Transplant Recipients

M. Vacha, A. Hulbert, J. Byrns, C. Benedetti, A. Finlen Copeland, A. Gray, S. Palmer, L. Snyder.
Both Preformed and De Novo Cw Donor Specific Antibodies Are Clinically Significant in Renal Transplantation

A. Gueret-Wardle, M. Willicombe, V. Dibbur, P. Brookes, A. McLean, D. Taube.
Bridging Therapy With Belatacept in High MELD Liver Transplant Recipients

T. Sparkes,¹ B. Masters,¹ S. Hanish,² D. Potosky,² W. Hutson,² J. LaMattina,² R. Barth.²
Broader Geographic Sharing of Adolescent Lung Donors Improves Allocation Efficiency

W. Tsuang,¹ J. Pyke,² M. Skeans,² K. Chan,⁴ T. Wozniak,³ A. Israni,² M. Hertz,⁴ B. Kasiske,² M. Valapour,¹ J. Snyder.²
Burden of Early Antibody-Mediated Rejection (AMR): Complications, Resource Utilization and Cost-Differential in Treatment of AMR

R. Banga,¹ C. Schinstock,¹ A. Boscoe,⁴ M. Hathcock,³ W. Kremers,³ M. Stegall.²

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z